- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02374801
Continued Access Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D (RESPOND-CAS)
Continued Access Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the Paradym RF SonR CRT-D
Study Overview
Status
Intervention / Treatment
Detailed Description
Since the introduction of cardiac resynchronization therapy (CRT) on a large scale, it has been observed that approximately 30% of recipient patients are non-responsive to therapy. This non-responsiveness can be decreased by optimizing the device programming, particularly the stimulation rate, paced and sensed atrioventricular (AV) delay, and the interventricular (VV) delay.
All CRT patients need a 100% rate of ventricular capture, but beyond this the achievement of therapy effectiveness requires the identification of the optimal pacing configuration, which varies among patients. The optimization of CRT systems, usually based on ultrasound imaging is time-consuming and the number of patients in need of multiple optimization procedures due to ventricular remodeling is growing rapidly.
The mechanical effects of a more coordinated contraction result in a shortening of the isovolumetric contraction phase and the pre-ejection time, and an increase in LV dP/dt (change in left ventricular pressure over time. The concept of measuring contractility with an implantable accelerometer was first clinically validated through a multicenter study on a rate responsive pacing system (BEST - Living from SORIN Biomedica) in 1996. This study positively demonstrates that measurement of Peak Endocardial Acceleration signal (called PEA or SonR) is feasible and reliable in the long-term, both for the purpose of rate response and as a hemodynamic monitor of cardiac function.
More recent clinical studies have demonstrated that optimal VV and AV Delays determined using algorithms based on SonR signal analysis (SonR method) are correlated with the highest hemodynamic improvement and lead to significant clinical benefit for the patients, thus reducing the rate of non-responsiveness to CRT therapy.
Therefore, frequent and automatic AV and VV delay optimization in patients with CRT-D devices could benefit both patients, through increasing the percent of CRT responders, and clinicians, through simplifying CRT optimization.
The inclusion phase of the "Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D" (RESPOND CRT Study, code ITSY06) has been completed. A total of 1039 patients have been enrolled in 125 centers in Europe, Australia and USA, from 13 January 2012 to 14 October 2014.
Safety has been monitored continuously throughout the RESPOND-CRT trial by the Data Safety Monitoring Board (DSMB). The DSMB charter is to provide recommendations to the Sponsor to suspend or stop the study if there is clear evidence of harm or harmful side-effects related to the use of the device or study procedures. To date, there have been no safety concerns raised by the RESPOND-CRT study data and the DSMB has recommended continuation of the clinical study.
Additionally, safety is supported by the European marketing history. As the SonR System is CE marked, RESPONDCRT is being conducted as a post-market study in Europe. Therefore in addition to the 1000+ patients enrolled in the RESPOND-CRT IDE, an additional 3000+ patients have received the SonR system outside the study.
As a supplement to the RESPOND CRT IDE Study a Continued Access Study (CAS) is being conducted according to the potential public health need and preliminary evidence that the device is likely to be effective with no significant safety concerns for the proposed indication.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals of Cleveland
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients who meet all the following criteria at the time of enrollment may be included:
- Patient with a class I and IIa indication for implantation of a CRT-D device according to current available guidelines
- Moderate/Severe HF (NYHA Class III or ambulatory IV)
- LVEF ≤ 35 %
- LBBB: QRS ≥ 120 ms ; non-LBBB : QRS ≥ 150 ms
- On a stable optimal drug regimen
- Patient is in sinus rhythm at the time of signing the informed consent
- Signed and dated informed consent
Exclusion Criteria:
Patients who meet any one of these criteria will be excluded from the investigation:
- Ventricular tachyarrhythmia of transient or reversible causes such as acute myocardial infarction, digitalis intoxication, drowning, electrocution, electrolyte imbalance, hypoxia or sepsis, uncorrected at the time of the enrollment
- Incessant ventricular tachyarrhythmia
- Unstable angina, or MI, CABG, or PTCA within the past 4 weeks
- Correctable valvular disease that is the primary cause of heart failure
- Recent CVA or TIA (within the previous 3 months)
- Persistent or permanent atrial arrhythmias (or cardioversion for atrial fibrillation) within the past month**
- Post heart transplant (patients who are waiting for a heart transplant are allowed in the study)
- Renal failure (GFR<15 ml/min/1.73m2) or on dialysis
- Previous implant with a CRT- P or CRT-D device
- Concurrent implant with another pacemaker or ICD system in which all or some of the components will not be extracted and/or utilized in the new system. Previously implanted RA leads must be removed prior to implant of the SonRtip lead.
- Already included in another clinical study that could confound the results of this study
- Life expectancy less than 1 year
- Inability to understand the purpose of the study or to understand and complete the QOL questionnaire
- Unavailability for scheduled follow-up or refusal to cooperate
- Sensitivity to 1 mg Dexamethasone sodium phosphate (DSP)
- Age of less than 18 years
- Pregnancy
- Substance addiction or abuse
- Under guardianship
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
This is a single-arm trial.
All patients will be implanted with the PARADYM RF SONR CRT-D device and the SonRtip bipolar atrial lead.
After successful implant, all patients will be programmed with the SonR automatic optimization feature turned ON ("AV+VV").
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute SonRtip Lead Complication-Free Rate
Time Frame: Month 3
|
All patients implanted with the SonRtip lead
|
Month 3
|
Chronic SonRtip Lead Complication-Free Rate
Time Frame: From month 3 to month 12
|
All patients implanted with the SonRtip lead
|
From month 3 to month 12
|
SonRtip Lead, pacing threshold
Time Frame: 12 months
|
All patients implanted with the SonRtip lead
|
12 months
|
SonRtip Lead, sensing amplitude
Time Frame: 12 months
|
All patients implanted with the SonRtip lead
|
12 months
|
SonRtip Lead, pacing impedance
Time Frame: 12 months
|
All patients implanted with the SonRtip lead
|
12 months
|
Report deaths from any cause
Time Frame: 12 months
|
All patients enrolled
|
12 months
|
Report HF-related events
Time Frame: 12 months
|
All patients implanted with the entire system
|
12 months
|
Report Quality of Life improvement
Time Frame: 12 months
|
All patients implanted with the entire system
|
12 months
|
Report NYHA class improvement
Time Frame: 12 months
|
All patients implanted with the entire system
|
12 months
|
Report echocardiographic parameters trend
Time Frame: Month 12
|
All patients implanted with the entire system
|
Month 12
|
Report Adverse Events
Time Frame: 12 months
|
All patients enrolled
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jagmeet P. Singh, M.D., Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ITSY10
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure (NYHA Class III and Ambulatory IV)
-
MicroPort CRMSorin CRMUnknownHeart Failure NYHA Class III and Ambulatory IVUnited States, Spain, United Kingdom, Germany, Italy, Australia, Netherlands, Portugal, France, Austria, Switzerland, Slovenia
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI)RecruitingHeart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IVUnited States
-
Comunicare Solutions SAKU Leuven; Jessa Hospital; Cliniques universitaires Saint-Luc- Université Catholique... and other collaboratorsRecruitingHeart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IVBelgium
-
Elpen Pharmaceutical Co. Inc.WithdrawnHeart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IV
-
University of LouisvilleThoratec CorporationUnknownHeart Failure NYHA Class III | Heart Failure NYHA Class IVUnited States
-
University Hospital, Gentofte, CopenhagenUnknownChronic Heart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IVDenmark
-
John ParissisCompletedHeart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IV | Heart Failure NYHA Class IGreece
-
Alexandria UniversityCompletedHeart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IVEgypt
-
NuPulseCVUnknownHeart Failure NYHA Class III | Heart Failure NYHA Class IVUnited States
-
University of Turin, ItalyCompletedHeart Failure NYHA Class III | Heart Failure NYHA Class IVItaly